BioCorRx Inc.

Equities

BICX

US09073C2052

Healthcare Facilities & Services

Market Closed - OTC Markets Other stock markets 11:36:28 2024-04-26 am EDT			5-day change	1st Jan Change
0.75 ^USD	-8.54%		-48.98%	-3.85%

Apr. 03	BioCorRx Inc. Announces Board Resignations	CI
Apr. 01	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 14, 2023 at 11:37 am EST

BioCorRx Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.010145 million compared to USD 0.094441 million a year ago. Net loss was USD 0.86628 million compared to USD 0.949118 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.13 a year ago.
For the nine months, sales was USD 0.070222 million compared to USD 0.130961 million a year ago. Net loss was USD 2.8 million compared to USD 3.21 million a year ago. Basic loss per share from continuing operations was USD 0.34 compared to USD 0.46 a year ago.

Latest news about BioCorRx Inc.

BioCorRx Inc. Announces Board Resignations	Apr. 03	CI
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
BioCorRx Pharmaceuticals Inc. Appoints Kate Devarney to the Board of Directors	Feb. 08	CI
BioCorRx Inc. Announces President Changes	Jan. 05	CI
BioCorRx Inc. announced that it has received $0.2 million in funding	Dec. 07	CI
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
BioCorRx Inc. announced that it has received $0.2 million in funding	Nov. 09	CI
Biocorrx Inc. Announces Management Changes	Nov. 02	CI
BioCorRx Inc. Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	23-08-15	CI
BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Insider Buy: Biocorrx	23-04-05	MT
BioCorRx Inc. announced that it has received $0.299983 million in funding	23-04-03	CI
BioCorRx Inc. announced that it has received $0.599536 million in funding	23-04-02	CI
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
BioCorRx Inc. announced that it expects to receive $0.599536 million in funding	23-03-28	CI
BioCorRx Inc. Announces Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial At 4Th Annual NIH HEAL Initiative Investigator Meeting	23-03-07	CI
BioCorRx Inc. Appoints Harsha Murthy as A Member of the Board of Directors	23-01-23	CI
BioCorRx Inc. Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder, Which is Being Developed Under BioCorRx Pharmaceuticals, Inc	23-01-19	CI
BioCorRx Inc. Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States	22-12-07	CI
BioCorRx Inc. agreed to Spin-Off BioCorRx Pharmaceuticals, Inc.	22-11-21	CI
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
BioCorRx Inc. Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104	22-10-13	CI
BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI

Chart BioCorRx Inc.

Duration

Period

More charts

Company Profile

BioCorRx Inc., through its subsidiaries, develops and provides addiction treatment solutions for the treatment of substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. The Company, through its subsidiary, BioCorRx Pharmaceuticals Inc., is engaged in the development of BICX104, a subcutaneous implantable naltrexone pellet for the treatment of both opioid and alcohol use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.

Sector

Healthcare Facilities & Services

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
BIOCORRX INC.	-3.85%	6.67M
CVS HEALTH CORPORATION	-14.92%	84.68B
HCA HEALTHCARE, INC.	+13.30%	81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+11.62%	29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B
FRESENIUS SE & CO. KGAA	-3.06%	16.36B
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B
PURE HEALTH HOLDING	-31.75%	11.77B
FRESENIUS MEDICAL CARE AG	-1.42%	11.72B
DAVITA INC.	+27.44%	11.71B

Other Healthcare Facilities & Services